Corbus Pharmaceuticals Holdings, Inc.
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $0
- Net income
- -$78.5M
- Total assets
- $168.2M
- Market cap
- $140.1M
- Operating margin
- -1542.7%
- Net margin
- -1420.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $5.5M
- Operating expenses
- $85.3M
- Operating income
- -$85.3M
- Income tax
- $0
- Net income
- -$78.5M
- EPS (basic)
- $-5.90
- EPS (diluted)
- $-5.90
Balance sheet
- Total assets
- $168.2M
- Current assets
- $167.0M
- Total liabilities
- $20.7M
- Current liabilities
- $20.7M
- Shareholders’ equity
- $147.5M
Cash flow
- Operating cash flow
- -$64.5M
- Investing cash flow
- -$1.6M
- Financing cash flow
- $77.4M
- Net cash flow
- $11.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $140.1M
- EPS (diluted)
- $-5.9
- Shares outstanding
- 18.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 24, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $78.5M in FY2022.
- Revenue grew 527% from FY2021 to FY2025.
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Corbus Pharmaceuticals Holdings, Inc..
Write a review
News about Corbus Pharmaceuticals Holdings, Inc.
News & sentiment via Polygon.io
